GlaxoSmithKline plc (GSK.L) (LON:GSK) Given a GBX 1,580 Price Target at Credit Suisse Group

Credit Suisse Group set a GBX 1,580 ($20.64) price target on GlaxoSmithKline plc (GSK.L) (LON:GSK) in a research report report published on Friday morning, Borsen Zeitung reports. The brokerage currently has a neutral rating on the stock.

Several other equities research analysts have also recently weighed in on GSK. Goldman Sachs Group reaffirmed a buy rating and set a GBX 2,000 ($26.13) price objective on shares of GlaxoSmithKline plc (GSK.L) in a research report on Tuesday, October 13th. Berenberg Bank reaffirmed a buy rating and set a GBX 1,800 ($23.52) price target on shares of GlaxoSmithKline plc (GSK.L) in a report on Tuesday, September 29th. Shore Capital reissued a sell rating on shares of GlaxoSmithKline plc (GSK.L) in a research note on Thursday, October 15th. Barclays restated an underweight rating on shares of GlaxoSmithKline plc (GSK.L) in a research report on Wednesday, July 29th. Finally, DZ Bank reduced their target price on GlaxoSmithKline plc (GSK.L) from GBX 1,900 ($24.82) to GBX 1,850 ($24.17) and set a buy rating on the stock in a report on Friday, July 31st. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and seven have assigned a buy rating to the company. The company has a consensus rating of Hold and a consensus target price of GBX 1,815.19 ($23.72).

LON:GSK opened at GBX 1,344.80 ($17.57) on Friday. GlaxoSmithKline plc has a 52 week low of GBX 1,324.40 ($17.30) and a 52 week high of GBX 1,857 ($24.26). The firm has a market cap of $72.48 billion and a price-to-earnings ratio of 10.13. The firm’s 50-day simple moving average is GBX 1,454.70 and its 200 day simple moving average is GBX 1,570.94. The company has a debt-to-equity ratio of 157.37, a quick ratio of 0.66 and a current ratio of 0.96.

GlaxoSmithKline plc (GSK.L) (LON:GSK) last announced its earnings results on Wednesday, July 29th. The company reported GBX 56.90 ($0.74) earnings per share (EPS) for the quarter. Sell-side analysts anticipate that GlaxoSmithKline plc will post 11384.9998941 EPS for the current year.

The company also recently announced a dividend, which was paid on Thursday, October 8th. Investors of record on Thursday, August 13th were paid a dividend of GBX 19 ($0.25) per share. This represents a yield of 1.22%. The ex-dividend date was Thursday, August 13th. GlaxoSmithKline plc (GSK.L)’s dividend payout ratio is presently 57.27%.

GlaxoSmithKline plc (GSK.L) Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Recommended Story: Trading signals using Bollinger bands

Analyst Recommendations for GlaxoSmithKline plc (GSK.L) (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc (GSK.L) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc (GSK.L) and related companies with's FREE daily email newsletter.